
    
      The main purposes: to determine the progression-free survival (PFS) and overall survival (OS)
      of gastric cancer patients given irinotecan + epirubicin as second-line treatment, who are at
      Stage IV with disease progressed or recurred after first-line chemotherapy failed, ,

      The Secondary purposes: to determine disease control rate (Disease Control Rate, DCR), the
      objective response rate (Object Response rate, ORR) and the Quality of life (Quality Of Life,
      QOL)
    
  